Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity

JCI Insight(2024)10.1172/jci.insight.173469Source: DataRank Database

Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity is a research paper published in JCI Insight (2024). On theSindex it has a DataRank of 0.495. It has been cited 13 times, with 9 citing works in its 1-hop citation network.

N/A

0.495DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access13 citations · 9 citing works in its network

Download PDF

Cite:

Linked data & code

geo nct pdb

Data availability

Repositories this paper deposited data in (declared in PubMed).

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (23 grants)Impact (FWCI 3.58)OA: goldTopics (43)IDs (PubMed, PMC, OpenAlex)Annotations (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 80%Citation Network 20%

Base Score Contribution

0.396

From this paper's citation signal

Citation Network Contribution

0.0988

From 6 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 9 citers.

Immunomodulatory properties of an arabinan polysaccharide extracted from Sida cordifolia: isolation, characterization and in vitro mechanism of action
Carbohydrate Polymers202510 citations67 referencesContributes 0.036
The Lasting Impact of IL-2: Approaching 50 Years of Advancing Immune Tolerance, Cancer Immunotherapies, and Autoimmune Diseases
Immunological Investigations20255 citations65 referencesContributes 0.028
Engineering cytokines for tumor-targeting and selective T cell activation
Trends in Molecular Medicine202516 citations109 referencesContributes 0.026
Harnessing cytokine immunocomplexes and cytokine fusion proteins for cancer Therapy: Mechanisms and clinical potential
Cancer Treatment Reviews20257 citations146 referencesContributes 0.014
IL-7 Immunotherapies: Current Applications and Engineering Opportunities
Immunological Investigations20251 citations99 referencesContributes 0.007

Authors (21)

Jakub Tomala ORCID,Joseph R. Gould ORCID,Michael I. Leff,Jian-Xin Lin ORCID,Peng Li ORCID

Live enrichment

PubMed:39115939 PMC:PMC11457862 OpenAlex:https://openalex.org/W4401420412

U.S. Department of Defense

Grant: W81XWH1810735,W81XWH21P0031

National Institutes of Health

Grant: R21CA249381,R01EB029455,R01EB029341

Maryland Stem Cell Research Fund

Grant: 2019-MSCRFD-5039

V Foundation for Cancer Research

Grant: V2018-005

Bladder Cancer Action Network

Grant: GC 10790-01

Emerson Collective Cancer Research Fund

Grant: N/A

Charles University

Grant: GAUK 285423

Czech Academy of Sciences

Grant: RVO 86652036

Institute of Microbiology of the Czech Academy of Sciences

Grant: RVO 61388971

National Institute for Cancer Research

Grant: LX22NPO5102

Czech Centre for Phenogenomics at the Institute of Molecular Genetics

Grant: RVO 68378050,LM2018126

National Institutes of Health Training Grant

Grant: K12GM123914 01A1

National Institutes of Health

Grant: T32 GM135131

NIGMS NIH HHS

Grant: K12 GM123914

NIGMS NIH HHS

Grant: T32 GM007057

NIGMS NIH HHS

Grant: T32 GM080189

NIBIB NIH HHS

Grant: R01 EB029341

NCI NIH HHS

Grant: R21 CA249381

NIBIB NIH HHS

Grant: R01 EB029455

NIH HHS

Grant: S10 OD034322

NIGMS NIH HHS

Grant: T32 GM149382

National Institutes of Health

Grant: 5R21CA249381-02

OPTIMIZING THE PRE-CLINICAL DEVELOPMENT OF IMMUNOTHERAPEUTIC ANTIBODIES THROUGH GLYCOENGINEERING

National Institutes of Health

Grant: 5K12GM123914-03

ASPIRE - A Joint Johns Hopkins, Morgan State and Coppin State IRACDA Program

FWCI

3.58

Citation Percentile

0.9%

Citation Trend

2023

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1172/jci.insight.173469

publisherhttps://doi.org/10.1172/jci.insight.173469

publisherhttps://insight.jci.org/articles/view/173469/files/pdf

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39115939

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11457862

Fields of Study

Monoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy researchViral Infectious Diseases and Gene Expression in Insects03 medical and health sciences0302 clinical medicine

MeSH Terms

AnimalsFemaleHumansInterleukin-2Mice, Inbred C57BLNeoplasmsRecombinant Fusion ProteinsProtein EngineeringCytokinesCell Line, TumorT-Lymphocytes, RegulatoryMice

Keywords

CytokineImmune systemEffectorAntibodyFusion proteinCancer researchImmunologyBiologyBiochemistryRecombinant DNACytokinesDrug therapyTherapeuticsCancer ImmunotherapyRecombinant Fusion ProteinsProtein EngineeringT-Lymphocytes, RegulatoryMice, Inbred C57BLMiceCell Line, TumorNeoplasmsInterleukin-2AnimalsHumansFemaleResearch Article